Kabavir-ZL

Kabavir-ZL

Kabavir ZL generic is a mixed combination of three compositions, which are Abacavir Sulphate, Zidovudine, and Lamivudine. It is a new formulation of triple nucleoside analogue RT inhibitors that works by decreasing the proportion of human immunodeficiency virus in the blood.

Abacavir is a variant of a carbocyclic synthetic nucleoside. Molecular enzymes transform abacavir into carbocyclic nucleoside triphosphate, an analogue of deoxyguanosine-5′-triphosphate that is a bioactive metabolite. Incorporating into viral deoxyribonucleic acid and competing with the organic enzyme gGTP, CBV-TP inhibits reverse transcriptase activity.

Dehydrogenase, which produces the 5′-carboxylic acid, and glucuronyl transferase, which produces the 5′-glucuronide, effectively remove this.

An analogue of a synthetic nucleoside is lamivudine. It stimulates internal phosphorylation, which results in lamivudine triphosphate; this is the process of adding a phosphate group to a molecule. That is an active 5’ triphosphate metabolite. After a structural analogue of nucleoside is combined, the 3’ phosphate source of action is the inhibition of reverse transcriptase by deoxyribonucleic acid chain termination. They widely disperse and absorb it. When cells phosphorylate zidovudine, they form zidovudine triphosphate, its functional 5'triphosphate metabolite. This composition is a potent inhibitor of human immunodeficiency virus replication and functions as a chain dideoxynucleoside of viral DNA during reverse transcription. It enhances immunological function and reverses the neurological dysfunction caused by HIV and related abnormalities.

Antiretroviral Therapy

Nucleotide reverse transcriptionase inhibitors engage with endogenous deoxynucleotides in order to incorporate them into virus-expanding DNA development. On the other side it does not include a 3’-hydroxyl group in the deoxyribose molecule. Non-NRTIs engage straight to reverse transcriptase and may inhibit it. Enzyme inhibitors bind to HIV protease, inhibiting the proteolytic cleavage of protein precursors required for the production of viral particles. Its fusion inhibitors limit HIV virions from combining, attaching, and entering cells Enfuvirtide has bound Gp41, which avoids membrane adhesion.

• COMPOSITION
• MODE OF USE
• WARNINGS